← Back to Screener
vTv Therapeutics Inc. Class A Common Stock (VTVT)
Price$37.75
Favorite Metrics
Price vs S&P 500 (26W)57.79%
Price vs S&P 500 (4W)-3.60%
Market Capitalization$159.33M
All Metrics
Book Value / Share (Quarterly)$16.36
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)-36.70%
Cash Flow / Share (Quarterly)$-6.41
Price vs S&P 500 (YTD)-8.81%
Net Profit Margin (TTM)-835.69%
EPS (TTM)$-3.34
10-Day Avg Trading Volume0.05M
EPS Excl Extra (TTM)$-3.34
Revenue Growth (5Y)-18.10%
EPS (Annual)$-3.20
ROI (Annual)-41.86%
Net Profit Margin (5Y Avg)-738.57%
Cash / Share (Quarterly)$22.58
ROA (Last FY)-30.00%
Revenue Growth TTM (YoY)-98.30%
EBITD / Share (TTM)$-3.91
Operating Margin (TTM)-1034.32%
Cash Flow / Share (Annual)$-6.41
P/B Ratio2.47x
P/B Ratio (Quarterly)2.59x
Net Income / Employee (Annual)$-1
EV / Revenue (TTM)69.22x
Net Interest Coverage (TTM)-1761.00x
ROA (TTM)-43.53%
EPS Incl Extra (Annual)$-3.20
Current Ratio (Annual)13.54x
Quick Ratio (Quarterly)13.42x
3-Month Avg Trading Volume0.04M
52-Week Price Return-69.59%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$-1.00
P/S Ratio (Annual)156.67x
Asset Turnover (Annual)0.03x
52-Week High$44.00
Operating Margin (5Y Avg)-995.06%
EPS Excl Extra (Annual)$-3.20
26-Week Price Return66.54%
Quick Ratio (Annual)13.42x
13-Week Price Return-4.72%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)13.54x
Enterprise Value$70.396
Revenue / Share Growth (5Y)14.10%
Asset Turnover (TTM)0.02x
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-2222.71%
Cash / Share (Annual)$22.58
3-Month Return Std Dev88.45%
Net Income / Employee (TTM)$-1
ROE (Last FY)-41.86%
Net Interest Coverage (Annual)-541.50x
EPS Basic Excl Extra (Annual)$-3.20
Receivables Turnover (TTM)12.40x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-3.34
Receivables Turnover (Annual)12.40x
ROI (TTM)-73.91%
P/S Ratio (TTM)156.67x
Pretax Margin (5Y Avg)-976.86%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$-0.43
Price vs S&P 500 (52W)-73.14%
Year-to-Date Return-4.68%
5-Day Price Return2.75%
EPS Normalized (Annual)$-3.20
ROA (5Y Avg)-74.14%
Net Profit Margin (Annual)-1815.34%
Month-to-Date Return-3.88%
Cash Flow / Share (TTM)$-13.50
EBITD / Share (Annual)$-3.91
Operating Margin (Annual)-2377.58%
EPS Basic Excl Extra (TTM)$-3.34
P/B Ratio (Annual)2.59x
Pretax Margin (TTM)-1018.29%
Book Value / Share (Annual)$16.36
Price vs S&P 500 (13W)-7.59%
Beta0.39x
Revenue / Share (TTM)$0.00
ROE (TTM)-74.07%
52-Week Low$14.00
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.22
4.18
4.18
4.18
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
VTVTvTv Therapeutics Inc. Class A Common Stock | 156.67x | -98.30% | — | — | $37.75 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
vTv Therapeutics is a late-stage biopharmaceutical company developing oral, small molecule drug candidates for diabetes and chronic diseases. The company's clinical pipeline is led by cadisegliatin, currently in Phase 3 trials, a potential first-in-class oral glucokinase activator for type 1 diabetes. vTv has a diverse pipeline of additional molecules in development across multiple disease indications.